Update shared on21 Oct 2025
Fair value Decreased 2.42%Analysts have slightly reduced their price target for Prestige Consumer Healthcare from $82.80 to $80.80. This change is due to marginal adjustments to projected valuation metrics and profit assumptions.
What's in the News
- The company completed a share buyback, repurchasing 410,446 shares between April 1, 2025 and June 30, 2025. In total, 1,148,118 shares have been bought back under the program announced on May 14, 2024, at a cost of $86.18 million (Key Developments).
- Prestige Consumer Healthcare Inc. is actively seeking mergers and acquisitions. Management emphasizes a disciplined approach and highlights approximately $1 billion in anticipated free cash flow over the next four years to support these initiatives (Key Developments).
- The company has lowered its fiscal 2026 earnings guidance. Expected revenue is now in the range of $1,100 million to $1,115 million, down from previous estimates of $1,140 million to $1,155 million. Diluted EPS is now forecasted at $4.50 to $4.58, compared to prior guidance of $4.70 to $4.82 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $82.80 to $80.80, reflecting a minor downward adjustment.
- Discount Rate remains unchanged at 6.78%.
- Revenue Growth estimate is essentially stable, moving from 1.0042x to 1.0042x.
- Net Profit Margin is virtually flat, holding at approximately 20.47%.
- Future P/E is lower, falling from 20.48x to 19.99x. This indicates a slightly more conservative outlook.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.